Spotlight
Clinical
Video Series
News
Partners
CME/CE
Subscribe
Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer
Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.
Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.
Click here to view the full-text version of this article.
Related Videos
Related Content
